Cytarabine is a medication used in chemotherapy to treat acute myeloid leukaemia (AML). It works by interfering with DNA synthesis during the S-phase of the cell cycle and inhibiting DNA polymerase.

Allopurinol is a medication that inhibits xanthine oxidase, which prevents the production of uric acid. It is commonly used to treat gout, but can also be used to prevent hyperuricaemia in high-grade lymphoma and leukaemia before chemotherapy treatment.

Methotrexate works by inhibiting dihydrofolate reductase and thymidylate synthesis. It is used to treat rheumatoid arthritis and various types of cancer.

Ondansetron is an anti-emetic medication that is used to prevent nausea during chemotherapy treatment. It works by selectively blocking serotonin receptors (5-HT3) in the chemoreceptor trigger zone (CTZ) of the medulla.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

The ideal blood type for the patient would be B rhesus negative, but it is not available. Among the available options, rhesus positive blood is not recommended for a woman of reproductive age as it may lead to haemolytic disease in newborns. A-type blood would also cause hemolysis in this patient. The only suitable option is O rhesus negative, which is the universal donor.

Blood product transfusion complications can be categorized into immunological, infective, and other complications. Immunological complications include acute haemolytic reactions, non-haemolytic febrile reactions, and allergic/anaphylaxis reactions. Infective complications may arise due to transmission of vCJD, although measures have been taken to minimize this risk. Other complications include transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), hyperkalaemia, iron overload, and clotting.

Non-haemolytic febrile reactions are thought to be caused by antibodies reacting with white cell fragments in the blood product and cytokines that have leaked from the blood cell during storage. These reactions may occur in 1-2% of red cell transfusions and 10-30% of platelet transfusions. Minor allergic reactions may also occur due to foreign plasma proteins, while anaphylaxis may be caused by patients with IgA deficiency who have anti-IgA antibodies.

Acute haemolytic transfusion reaction is a serious complication that results from a mismatch of blood group (ABO) which causes massive intravascular haemolysis. Symptoms begin minutes after the transfusion is started and include a fever, abdominal and chest pain, agitation, and hypotension. Treatment should include immediate transfusion termination, generous fluid resuscitation with saline solution, and informing the lab. Complications include disseminated intravascular coagulation and renal failure.

TRALI is a rare but potentially fatal complication of blood transfusion that is characterized by the development of hypoxaemia/acute respiratory distress syndrome within 6 hours of transfusion. On the other hand, TACO is a relatively common reaction due to fluid overload resulting in pulmonary oedema. As well as features of pulmonary oedema, the patient may also be hypertensive, a key difference from patients with TRALI.

Increased osteoclast activity in response to cytokines released by myeloma cells is the primary cause of hypercalcaemia in multiple myeloma, which typically affects individuals aged 60-70 years and presents with bone pain or pathological fractures from osteolytic lesions. Hypercalcaemia in kidney failure is associated with hyperphosphataemia and does not cause bone pain. Elevated calcitriol levels are linked to granulomatous disorders like sarcoidosis and tuberculosis, which do not typically cause bone pain. Rebound hypercalcaemia occurs after rhabdomyolysis, which usually results from a fall and long lie. Although primary hyperparathyroidism is a common cause of hypercalcaemia and can lead to bone pain or pathological fractures, it is not associated with anaemia.

Understanding Multiple Myeloma: Features and Investigations

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is most commonly found in patients aged 60-70 years. The disease is characterized by a range of symptoms, which can be remembered using the mnemonic CRABBI. These include hypercalcemia, renal damage, anemia, bleeding, bone lesions, and increased susceptibility to infection. Other features of multiple myeloma include amyloidosis, carpal tunnel syndrome, neuropathy, and hyperviscosity.

To diagnose multiple myeloma, a range of investigations are required. Blood tests can reveal anemia, renal failure, and hypercalcemia. Protein electrophoresis can detect raised levels of monoclonal IgA/IgG proteins in the serum, while bone marrow aspiration can confirm the diagnosis if the number of plasma cells is significantly raised. Imaging studies, such as whole-body MRI or X-rays, can be used to detect osteolytic lesions.

The diagnostic criteria for multiple myeloma require one major and one minor criteria or three minor criteria in an individual who has signs or symptoms of the disease. Major criteria include the presence of plasmacytoma, 30% plasma cells in a bone marrow sample, or elevated levels of M protein in the blood or urine. Minor criteria include 10% to 30% plasma cells in a bone marrow sample, minor elevations in the level of M protein in the blood or urine, osteolytic lesions, or low levels of antibodies in the blood. Understanding the features and investigations of multiple myeloma is crucial for early detection and effective treatment.

The lumbar lymph nodes, also referred to as the para-aortic lymph nodes, receive drainage from the ovary.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

Hodgkin’s disease is characterized by the presence of Reed Sternberg cells, while sarcoid is associated with the presence of all other cell types.

Chronic inflammation can occur as a result of acute inflammation or as a primary process. There are three main processes that can lead to chronic inflammation: persisting infection with certain organisms, prolonged exposure to non-biodegradable substances, and autoimmune conditions involving antibodies formed against host antigens. Acute inflammation involves changes to existing vascular structure and increased permeability of endothelial cells, as well as infiltration of neutrophils. In contrast, chronic inflammation is characterized by angiogenesis and the predominance of macrophages, plasma cells, and lymphocytes. The process may resolve with suppuration, complete resolution, abscess formation, or progression to chronic inflammation. Healing by fibrosis is the main result of chronic inflammation. Granulomas, which consist of a microscopic aggregation of macrophages, are pathognomonic of chronic inflammation and can be found in conditions such as colonic Crohn’s disease. Growth factors released by activated macrophages, such as interferon and fibroblast growth factor, may have systemic features resulting in systemic symptoms and signs in individuals with long-standing chronic inflammation.

The para-aortic nodes receive lymphatic drainage from the ovary through the gonadal vessels.

Lymphatic Drainage of Female Reproductive Organs

The lymphatic drainage of the female reproductive organs is a complex system that involves multiple nodal stations. The ovaries drain to the para-aortic lymphatics via the gonadal vessels. The uterine fundus has a lymphatic drainage that runs with the ovarian vessels and may thus drain to the para-aortic nodes. Some drainage may also pass along the round ligament to the inguinal nodes. The body of the uterus drains through lymphatics contained within the broad ligament to the iliac lymph nodes. The cervix drains into three potential nodal stations; laterally through the broad ligament to the external iliac nodes, along the lymphatics of the uterosacral fold to the presacral nodes and posterolaterally along lymphatics lying alongside the uterine vessels to the internal iliac nodes. Understanding the lymphatic drainage of the female reproductive organs is important for the diagnosis and treatment of gynecological cancers.

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

Ipilimumab is a type of immune checkpoint inhibitor that is used to treat melanoma by blocking CTLA-4. Other immune checkpoint inhibitors, such as nivolumab and pembrolizumab, block PD-1 and can be used to treat various cancers including melanoma, Hodgkin’s lymphoma, and non-small cell lung cancer. Atezolizumab and durvalumab are examples of immune checkpoint inhibitors that block PD-L1 and can be used to treat lung and urothelial cancer. Alkylating agents like cyclophosphamide exert their effect by cross-linking DNA, while medications like vincristine and vinblastine inhibit the formation of microtubules.

Understanding Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a type of immunotherapy that is becoming increasingly popular in the treatment of certain types of cancer. Unlike traditional therapies such as chemotherapy, these targeted treatments work by harnessing the body’s natural anti-cancer immune response. They boost the immune system’s ability to attack and destroy cancer cells, rather than directly affecting their growth and proliferation.

T-cells are an essential part of our immune system that helps destroy cancer cells. However, some cancer cells produce high levels of proteins that turn T-cells off. Checkpoint inhibitors block this process and reactivate and increase the body’s T-cell population, enhancing the immune system’s ability to recognize and fight cancer cells.

There are different types of immune checkpoint inhibitors, including Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, and Durvalumab. These drugs block specific proteins found on T-cells and cancer cells, such as CTLA-4, PD-1, and PD-L1. They are administered by injection or intravenous infusion and can be given as a single-agent treatment or combined with chemotherapy or each other.

However, the mechanism of action of these drugs can result in side effects termed ‘Immune-related adverse events’ that are inflammatory and autoimmune in nature. This is because all immune cells are boosted by these drugs, not just the ones that target cancer. The overactive T-cells can produce side effects such as dry, itchy skin and rashes, nausea and vomiting, decreased appetite, diarrhea, tiredness and fatigue, shortness of breath, and a dry cough. Management of such side effects reflects the inflammatory nature, often involving corticosteroids. It is important to monitor liver, kidney, and thyroid function as these drugs can affect these organs.

In conclusion, the early success of immune checkpoint inhibitors in solid tumors has generated tremendous interest in further developing and exploring these strategies across the oncology disease spectrum. Ongoing testing in clinical trials creates new hope for patients affected by other types of disease.

Common Tumours in Children Under 1 Year Old

Embryonal ‘-blastoma’ tumours are frequently found in children under 1 year old. These tumours include retinoblastoma, neuroblastoma, nephroblastoma, medulloblastoma, and hepatoblastoma. Among these, neuroblastoma is the most common and typically affects infants under 1 year old. It originates from neural crest cells in the adrenal medulla and often presents as a large abdominal mass in an otherwise healthy child.

Acute lymphoblastic leukaemia (ALL) is the most common cancer in children overall, but it is less common in infants under 1 year old. Unfortunately, the prognosis for those who develop ALL before their first birthday is poorer. Astrocytomas, the most common type of CNS tumour, tend to affect slightly older children.

Retinoblastomas are embryonal tumours of the retina, with half being spontaneous and the other half being familial due to an inherited mutation in the pRB tumour suppressor gene. Wilms’ tumour, also known as nephroblastoma, is another embryonal tumour that affects the kidneys and may present as an abdominal mass in infants.

In summary, embryonal ‘-blastoma’ tumours are common in children under 1 year old, with neuroblastoma being the most prevalent. Other tumours, such as ALL and astrocytomas, tend to affect slightly older children. Early detection and treatment are crucial for improving outcomes in these young patients.

Metastatic ovarian cancer is often first detected in the para-aortic lymph nodes, as this is where the ovaries drain. The fundus of the uterus drains to the deep inguinal nodes through lymphatics that follow the round ligament. The inferior mesenteric nodes receive drainage from the upper part of the rectum, sigmoid colon, and descending colon. The body of the uterus drains to the iliac nodes through lymphatics that follow the broad ligament, while parts of the cervix may drain to the presacral nodes via lymphatics that follow the uterosacral fold.

Lymphatic Drainage of Female Reproductive Organs

The lymphatic drainage of the female reproductive organs is a complex system that involves multiple nodal stations. The ovaries drain to the para-aortic lymphatics via the gonadal vessels. The uterine fundus has a lymphatic drainage that runs with the ovarian vessels and may thus drain to the para-aortic nodes. Some drainage may also pass along the round ligament to the inguinal nodes. The body of the uterus drains through lymphatics contained within the broad ligament to the iliac lymph nodes. The cervix drains into three potential nodal stations; laterally through the broad ligament to the external iliac nodes, along the lymphatics of the uterosacral fold to the presacral nodes and posterolaterally along lymphatics lying alongside the uterine vessels to the internal iliac nodes. Understanding the lymphatic drainage of the female reproductive organs is important for the diagnosis and treatment of gynecological cancers.

Warm autoimmune haemolytic anaemia involves IgG-mediated red blood cell destruction at body temperature, while IgM-mediated haemolysis is precipitated by the cold and affects the hands and feet. Other immunoglobulins such as IgA and IgE may also be involved.

Understanding Autoimmune Haemolytic Anaemia

Autoimmune haemolytic anaemia (AIHA) is a condition where the body’s immune system attacks its own red blood cells, leading to anaemia. There are two types of AIHA: warm and cold. Warm AIHA is the most common type and is caused by an antibody (usually IgG) that causes haemolysis at body temperature. It tends to occur in the spleen and is often idiopathic, but can also be secondary to autoimmune diseases, neoplasia, or drugs. On the other hand, cold AIHA is caused by an IgM antibody that causes haemolysis at 4°C and is more commonly intravascular. It is associated with neoplasia and infections, and patients may experience symptoms of Raynaud’s and acrocynaosis.

To diagnose AIHA, doctors look for general features of haemolytic anaemia, such as anaemia, reticulocytosis, low haptoglobin, raised lactate dehydrogenase (LDH) and indirect bilirubin, and spherocytes and reticulocytes on a blood film. A positive direct antiglobulin test (Coombs’ test) is specific for AIHA. Treatment for AIHA involves managing any underlying disorder and using steroids as first-line therapy, with rituximab as an option. However, patients with cold AIHA tend to respond less well to steroids.

In summary, AIHA is a condition where the immune system attacks red blood cells, leading to anaemia. Warm and cold AIHA are the two types, with warm being more common and caused by an IgG antibody that causes haemolysis at body temperature, while cold is caused by an IgM antibody that causes haemolysis at 4°C and is associated with neoplasia and infections. Diagnosis involves looking for general features of haemolytic anaemia and a positive direct antiglobulin test. Treatment involves managing any underlying disorder and using steroids as first-line therapy.

Athletes who use EPO are at risk of developing polycythemia. Cyclists are known to frequently use EPO, which can cause localized erythema on the abdomen from repeated injections. The patient’s headaches are not migrainous as they lack associated symptoms such as aura, photophobia, or phonophobia. Renal cell carcinoma is the primary type of kidney cancer in adults and typically presents with flank pain, haematuria, and a flank mass. Other symptoms may include weight loss, night sweats, fever, and malaise.

Polycythaemia is a condition that can be classified as relative, primary (polycythaemia rubra vera), or secondary. Relative polycythaemia can be caused by dehydration or stress, such as in Gaisbock syndrome. Primary polycythaemia rubra vera is a rare blood disorder that causes the bone marrow to produce too many red blood cells. Secondary polycythaemia can be caused by conditions such as COPD, altitude, obstructive sleep apnoea, or excessive erythropoietin production due to certain tumors or growths. To distinguish between true polycythaemia and relative polycythaemia, red cell mass studies may be used. In true polycythaemia, the total red cell mass in males is greater than 35 ml/kg and in women is greater than 32 ml/kg. Uterine fibroids may also cause polycythaemia indirectly by causing menorrhagia, but this is rarely a clinical problem.

The most probable reason for the patient’s fatigue and abnormal blood results is the side effect of phenytoin. Phenytoin is an antifolate medication that can lead to folate deficiency, resulting in macrocytic anaemia, which is evident in the patient’s blood test. Fatigue is a common symptom of anaemia, which the patient has reported.

Although lack of sleep may contribute to the patient’s tiredness, it alone cannot cause macrocytic anaemia.

Hypothyroidism can cause macrocytic anaemia and lethargy, but it is less likely to be the cause of the patient’s symptoms. The patient has no history of thyroid disorders, and his slim build and anxiety are more typical of hyperthyroidism.

Loratadine is a second-generation antihistamine that does not usually cause drowsiness.

Understanding Macrocytic Anaemia

Macrocytic anaemia is a type of anaemia that can be classified into two categories: megaloblastic and normoblastic. Megaloblastic anaemia is caused by a deficiency in vitamin B12 or folate, which leads to the production of abnormally large red blood cells in the bone marrow. This type of anaemia can also be caused by certain medications, alcohol, liver disease, hypothyroidism, pregnancy, and myelodysplasia.

On the other hand, normoblastic anaemia is caused by an increase in the number of immature red blood cells, known as reticulocytes, in the bone marrow. This can occur as a result of certain medications, such as methotrexate, or in response to other underlying medical conditions.

It is important to identify the underlying cause of macrocytic anaemia in order to provide appropriate treatment. This may involve addressing any nutritional deficiencies, managing underlying medical conditions, or adjusting medications. With proper management, most cases of macrocytic anaemia can be successfully treated.

The most probable diagnosis for this case is factor V Leiden, which is the most common inherited thrombophilia. This condition causes resistance to activated protein C, which normally breaks down clotting factor V to prevent excessive clotting. As a result, individuals with factor V Leiden have an increased risk of developing blood clots, particularly deep vein thrombosis.

Antiphospholipid syndrome is another thrombophilia, but it is an acquired autoimmune disorder that is less common than factor V Leiden. It is characterized by inappropriate clotting and miscarriage, which are not present in this case.

Haemophilia A and von Willebrand disease are bleeding disorders that increase the risk of excessive bleeding, not clotting. Therefore, they are unlikely to be the cause of the patient’s thrombosis.

Protein C deficiency has a similar mechanism and presentation to factor V Leiden, but it is less common. Hence, it is not the most probable diagnosis in this case.

Thrombophilia is a condition that causes an increased risk of blood clots. It can be inherited or acquired. Inherited thrombophilia is caused by genetic mutations that affect the body’s natural ability to prevent blood clots. The most common cause of inherited thrombophilia is a gain of function polymorphism called factor V Leiden, which affects the protein that helps regulate blood clotting. Other genetic mutations that can cause thrombophilia include deficiencies of naturally occurring anticoagulants such as antithrombin III, protein C, and protein S. The prevalence and relative risk of venous thromboembolism (VTE) vary depending on the specific genetic mutation.

Acquired thrombophilia can be caused by conditions such as antiphospholipid syndrome or the use of certain medications, such as the combined oral contraceptive pill. These conditions can affect the body’s natural ability to prevent blood clots and increase the risk of VTE. It is important to identify and manage thrombophilia to prevent serious complications such as deep vein thrombosis and pulmonary embolism.

The origin of eosinophils is from common myeloid progenitor cells. A patient with neutrophilia and low haemoglobin is likely to have chronic myeloid leukaemia (CML). CML is characterized by increased levels of all cells derived from the myeloid lineage, including basophils, monocytes, and eosinophils. The bone marrow biopsy is diagnostic for CML and typically shows the t(9;22) chromosomal translocation, also known as the Philadelphia chromosome. Imatinib, an inhibitor of the BCR-ABL fusion protein created with this translocation, is a common treatment for CML. Cells derived from common lymphoid progenitor cells are not affected in CML.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

Haemophilia A is characterized by prolonged APTT and reduced levels of factor 8:C, while bleeding time and PT remain normal. Cholestatic jaundice hinders the absorption of vitamin K, which is fat-soluble. Patients who undergo massive transfusions, equivalent to more than 10 units of blood or their entire blood volume, are at risk of thrombocytopenia, as well as deficiencies in factor 5 and 8.

Abnormal coagulation can be caused by various factors such as heparin, warfarin, disseminated intravascular coagulation (DIC), and liver disease. Heparin prevents the activation of factors 2, 9, 10, and 11, while warfarin affects the synthesis of factors 2, 7, 9, and 10. DIC affects factors 1, 2, 5, 8, and 11, and liver disease affects factors 1, 2, 5, 7, 9, 10, and 11.

When interpreting blood clotting test results, different disorders can be identified based on the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), and bleeding time. Haemophilia is characterized by increased APTT levels, normal PT levels, and normal bleeding time. On the other hand, von Willebrand’s disease is characterized by increased APTT levels, normal PT levels, and increased bleeding time. Lastly, vitamin K deficiency is characterized by increased APTT and PT levels, and normal bleeding time. Proper interpretation of these results is crucial in diagnosing and treating coagulation disorders.

GVHD occurs when T cells from the donor tissue attack the recipient’s cells. This often manifests as skin and gastrointestinal symptoms in a host who lacks T cells, following a bone marrow or stem cell transplant. The immune response is initiated by donor CD4+ T cells recognizing the recipient’s MHC II as foreign, while donor CD8+ T cells cause tissue damage.

Understanding Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can occur after bone marrow or solid organ transplantation. It happens when the T cells in the donor tissue attack the recipient’s cells. This is different from transplant rejection, where the recipient’s immune cells attack the donor tissue. GVHD is diagnosed using the Billingham criteria, which require that the transplanted tissue contains functioning immune cells, the donor and recipient are immunologically different, and the recipient is immunocompromised.

The incidence of GVHD varies, but it can occur in up to 50% of patients who receive allogeneic bone marrow transplants. Risk factors include poorly matched donor and recipient, the type of conditioning used before transplantation, gender disparity between donor and recipient, and the source of the graft.

Acute and chronic GVHD are considered separate syndromes. Acute GVHD typically occurs within 100 days of transplantation and affects the skin, liver, and gastrointestinal tract. Chronic GVHD may occur after acute disease or arise de novo and has a more varied clinical picture.

Diagnosis of GVHD is largely clinical and based on the exclusion of other pathology. Signs and symptoms of acute GVHD include a painful rash, jaundice, diarrhea, nausea, vomiting, and fever. Chronic GVHD can affect the skin, eyes, gastrointestinal tract, and lungs.

Treatment of GVHD involves immunosuppression and supportive measures. Intravenous steroids are the mainstay of treatment for severe cases of acute GVHD, while extended courses of steroid therapy are often needed in chronic GVHD. Second-line therapies include anti-TNF, mTOR inhibitors, and extracorporeal photopheresis. Topical steroid therapy may be sufficient in mild disease with limited cutaneous involvement. However, excessive immunosuppression may increase the risk of infection and limit the beneficial graft-versus-tumor effect of the transplant.

Lead poisoning can cause the accumulation of lead in the metaphysis of bones, which can be seen as bands of increased density on x-rays. In this case, the child’s recent deterioration in academic and physical performance, along with the history of moving to an old house, suggests the possibility of lead-based paint exposure. The presence of a lead line on the gums further supports this suspicion. While normocytic anemia can have many causes, the addition of radiodense lines in the metaphysis of long bones increases the likelihood of lead poisoning. Cretinism, caused by maternal hypothyroidism, typically presents earlier and has different symptoms. Osteomyelitis, an infection of the bone, has different x-ray findings. Sickle cell anemia and iron deficiency are not associated with the symptoms and x-ray findings in this case.

Lead poisoning is a condition that should be considered when a patient presents with abdominal pain and neurological symptoms, along with acute intermittent porphyria. This condition is caused by defective ferrochelatase and ALA dehydratase function. Symptoms of lead poisoning include abdominal pain, peripheral neuropathy (mainly motor), neuropsychiatric features, fatigue, constipation, and blue lines on the gum margin (which is rare in children and only present in 20% of adult patients).

To diagnose lead poisoning, doctors typically measure the patient’s blood lead level, with levels greater than 10 mcg/dl considered significant. A full blood count may also be performed, which can reveal microcytic anemia and red cell abnormalities such as basophilic stippling and clover-leaf morphology. Additionally, raised serum and urine levels of delta aminolaevulinic acid may be seen, which can sometimes make it difficult to differentiate from acute intermittent porphyria. Urinary coproporphyrin is also increased, while urinary porphobilinogen and uroporphyrin levels are normal to slightly increased. In children, lead can accumulate in the metaphysis of the bones, although x-rays are not typically part of the standard work-up.

Various chelating agents are currently used to manage lead poisoning, including dimercaptosuccinic acid (DMSA), D-penicillamine, EDTA, and dimercaprol. These agents work to remove the lead from the body and can help alleviate symptoms.

Irradiated blood products are utilized because they have been stripped of T-lymphocytes, which can trigger severe reactions and even death if recognized as foreign agents by the host. This special requirement is particularly necessary for patients who are vulnerable to TA-GvHD, such as those with immune deficiencies or Hodgkin’s lymphoma. On the other hand, CMV negative blood products are used to minimize the risk of CMV transmission in neonates or immunocompromised individuals. In some cases, washed blood products may be ordered for patients who experience recurrent severe allergic transfusion reactions or urticarial reactions that are not prevented by pre-transfusion antihistamine and corticosteroid administration. It is important to note that the depletion of B-lymphocytes is not a primary reason for using irradiated blood products, and there is no evidence that irradiation reduces the risk of TA-GvHD by depleting eosinophil count.

CMV Negative and Irradiated Blood Products

Blood products that are CMV negative and irradiated are used in specific situations to prevent certain complications. CMV is a virus that is transmitted through leucocytes, but as most blood products are now leucocyte depleted, CMV negative products are not often needed. However, in situations where CMV transmission is a concern, such as in granulocyte transfusions, intra-uterine transfusions, neonates up to 28 days post expected date of delivery, bone marrow/stem cell transplants, immunocompromised patients, and those with/previous Hodgkin lymphoma, CMV negative blood products are used.

On the other hand, irradiated blood products are depleted of T-lymphocytes and are used to prevent transfusion-associated graft versus host disease (TA-GVHD) caused by engraftment of viable donor T lymphocytes. Irradiated blood products are used in situations such as granulocyte transfusions, intra-uterine transfusions, neonates up to 28 days post expected date of delivery, bone marrow/stem cell transplants, and in patients who have received chemotherapy or have congenital immunodeficiencies.

In summary, CMV negative and irradiated blood products are used in specific situations to prevent complications related to CMV transmission and TA-GVHD. The use of these blood products is determined based on the patient’s medical history and condition.

Genetics of Haematological Malignancies

Haematological malignancies are cancers that affect the blood, bone marrow, and lymphatic system. These cancers are often associated with specific genetic abnormalities, such as translocations. Here are some common translocations and their associated haematological malignancies:

– Philadelphia chromosome (t(9;22)): This translocation is present in more than 95% of patients with chronic myeloid leukaemia (CML). It results in the fusion of the Abelson proto-oncogene with the BCR gene on chromosome 22, creating the BCR-ABL gene. This gene codes for a fusion protein with excessive tyrosine kinase activity, which is a poor prognostic indicator in acute lymphoblastic leukaemia (ALL).

– t(15;17): This translocation is seen in acute promyelocytic leukaemia (M3) and involves the fusion of the PML and RAR-alpha genes.

– t(8;14): Burkitt’s lymphoma is associated with this translocation, which involves the translocation of the MYC oncogene to an immunoglobulin gene.

– t(11;14): Mantle cell lymphoma is associated with the deregulation of the cyclin D1 (BCL-1) gene.

– t(14;18): Follicular lymphoma is associated with increased BCL-2 transcription due to this translocation.

Understanding the genetic abnormalities associated with haematological malignancies is important for diagnosis, prognosis, and treatment.

The initial impact of vitamin B12 deficiency is typically on the dorsal column, causing impairment in joint position and vibration perception before the onset of distal paraesthesia.

Vitamin B12 is essential for the development of red blood cells and the maintenance of the nervous system. It is absorbed through the binding of intrinsic factor, which is secreted by parietal cells in the stomach, and actively absorbed in the terminal ileum. A deficiency in vitamin B12 can be caused by pernicious anaemia, post gastrectomy, a vegan or poor diet, disorders or surgery of the terminal ileum, Crohn’s disease, or metformin use.

Symptoms of vitamin B12 deficiency include macrocytic anaemia, a sore tongue and mouth, neurological symptoms, and neuropsychiatric symptoms such as mood disturbances. The dorsal column is usually affected first, leading to joint position and vibration issues before distal paraesthesia.

Management of vitamin B12 deficiency involves administering 1 mg of IM hydroxocobalamin three times a week for two weeks, followed by once every three months if there is no neurological involvement. If a patient is also deficient in folic acid, it is important to treat the B12 deficiency first to avoid subacute combined degeneration of the cord.

Angiosarcoma of the liver is a tumor that is not commonly found. However, it has been associated with exposure to vinyl chloride, as seen in this instance. While current factories have taken measures to reduce exposure to this substance, this was not always the case.

Occupational cancers are responsible for 5.3% of cancer deaths, with men being more affected than women. The most common types of cancer in men include mesothelioma, bladder cancer, non-melanoma skin cancer, lung cancer, and sino-nasal cancer. Occupations that have a high risk of developing tumors include those in the construction industry, coal tar and pitch workers, miners, metalworkers, asbestos workers, and those in the rubber industry. Shift work has also been linked to breast cancer in women.

The latency period between exposure to carcinogens and the development of cancer is typically 15 years for solid tumors and 20 years for leukemia. Many occupational cancers are rare, such as sino-nasal cancer, which is linked to wood dust exposure and is not strongly associated with smoking. Another rare occupational tumor is angiosarcoma of the liver, which is linked to working with vinyl chloride. In non-occupational contexts, these tumors are extremely rare.

Hydroxyurea is a medication that is used to treat various diseases, including sickle cell disease and chronic myelogenous leukaemia. It works by inhibiting ribonucleotide reductase, which reduces the production of deoxyribonucleotides. This, in turn, inhibits cell synthesis by decreasing DNA synthesis. It is important to note that hydroxyurea does not work by causing the cross-linking of DNA, which is a mechanism used by other drugs such as Cisplatin. Methotrexate works through the inhibition of dihydrofolate reductase, while Irinotecan inhibits topoisomerase I, and Cytarabine is a pyrimidine antagonist. These drugs work through different mechanisms and are not related to hydroxyurea.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

Understanding Mantle Cell Lymphoma

Mantle cell lymphoma is a type of B-cell lymphoma that is characterized by the over-expression of the cyclin D1 (BCL-1) gene due to a translocation (11;14). This cancer is identified by the presence of CD5+, CD19+, CD22+, and CD23- markers. Unfortunately, mantle cell lymphoma has a poor prognosis and is often associated with widespread lymphadenopathy.

In summary, mantle cell lymphoma is a type of cancer that affects B-cells and is caused by a specific genetic translocation. It is identified by certain markers and is known for its poor prognosis and widespread lymphadenopathy. Understanding the basics of this disease can help with early detection and treatment.

The correct answer is T lymphocytes, as the thymus plays a role in their maturation. DiGeorge syndrome is caused by a microdeletion on chromosome 22, resulting in the failure of development of the third and fourth pharyngeal arches. The syndrome is characterized by cardiac abnormalities, abnormal facies, thymus aplasia, cleft palate, and hypoparathyroidism, which can be remembered with the acronym CATCH.

The Thymus Gland: Development, Structure, and Function

The thymus gland is an encapsulated organ that develops from the third and fourth pharyngeal pouches. It descends to the anterior superior mediastinum and is subdivided into lobules, each consisting of a cortex and a medulla. The cortex is made up of tightly packed lymphocytes, while the medulla is mostly composed of epithelial cells. Hassall’s corpuscles, which are concentrically arranged medullary epithelial cells that may surround a keratinized center, are also present.

The inferior parathyroid glands, which also develop from the third pharyngeal pouch, may be located with the thymus gland. The thymus gland’s arterial supply comes from the internal mammary artery or pericardiophrenic arteries, while its venous drainage is to the left brachiocephalic vein. The thymus gland plays a crucial role in the development and maturation of T-cells, which are essential for the immune system’s proper functioning.

Massive splenomegaly can be a symptom of chronic myeloid leukaemia (CML), which is the known diagnosis of this woman. Left-sided swelling, increased tendency to bruise or bleed, and abdominal pain may also be present. However, a duodenal ulcer is more likely to cause indigestion and is not commonly associated with CML. While hepatomegaly may occur in CML, it is less common and less marked than splenomegaly. Large bowel obstruction is not typically associated with CML, but may be a presenting symptom of undiagnosed colorectal cancer. Although splenic rupture can cause abdominal pain, it is more likely to lead to an acute presentation due to complications of acute intra-abdominal bleeding.

Understanding Chronic Myeloid Leukaemia and its Management

Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the presence of the Philadelphia chromosome in more than 95% of patients. This chromosome is formed due to a translocation between chromosomes 9 and 22, resulting in the fusion of the ABL proto-oncogene and the BCR gene. The resulting BCR-ABL gene produces a fusion protein that has excessive tyrosine kinase activity.

CML typically affects individuals between the ages of 60-70 years and presents with symptoms such as anaemia, weight loss, sweating, and splenomegaly. The condition is also associated with an increase in granulocytes at different stages of maturation and thrombocytosis. In some cases, CML may undergo blast transformation, leading to acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL).

The management of CML involves various treatment options, including imatinib, which is considered the first-line treatment. Imatinib is an inhibitor of the tyrosine kinase associated with the BCR-ABL defect and has a very high response rate in chronic phase CML. Other treatment options include hydroxyurea, interferon-alpha, and allogeneic bone marrow transplant. With proper management, individuals with CML can lead a normal life.

The lymphatic system of the breast is responsible for draining excess fluid and waste products. Lymph from the upper outer quadrant of the breast drains to the axillary lymph nodes, while lymph from the inner quadrants drains to the parasternal lymph nodes. Additionally, some lymph from the lower quadrants drains to the inferior phrenic lymph nodes.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

EDTA is known to induce pseudothrombocytopenia, which is a condition where platelet counts are falsely reported as low due to EDTA-dependent platelet aggregation. On the other hand, sodium fluoride inhibits glycolysis and prevents enzymes from functioning, leading to the depletion of substrates like glucose during storage. While sodium citrate, sodium oxalate, and lithium heparin are all anticoagulants commonly found in vacutainers, they are not linked to thrombocytopenia.

Causes of Thrombocytopenia

Thrombocytopenia is a medical condition characterized by a low platelet count in the blood. The severity of thrombocytopenia can vary, with some cases being more severe than others. Severe thrombocytopenia can be caused by conditions such as immune thrombocytopenia (ITP), disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), and haematological malignancy. On the other hand, moderate thrombocytopenia can be caused by heparin-induced thrombocytopenia (HIT), drug-induced factors such as quinine, diuretics, sulphonamides, aspirin, and thiazides, alcohol, liver disease, hypersplenism, viral infections such as EBV, HIV, and hepatitis, pregnancy, SLE/antiphospholipid syndrome, and vitamin B12 deficiency. It is important to note that pseudothrombocytopenia can also occur as a result of using EDTA as an anticoagulant.

The prothrombin time (PT) is used to assess the extrinsic pathway of the clotting cascade, while the activated partial thromboplastin time (aPTT) is used to assess the intrinsic pathway. The thrombin time is used to assess fibrin formation. A 50:50 mixing study is used to determine if a prolonged PT or aPTT is due to factor deficiency or a factor inhibitor.

The Coagulation Cascade: Two Pathways to Fibrin Formation

The coagulation cascade is a complex process that leads to the formation of a blood clot. There are two pathways that can lead to fibrin formation: the intrinsic pathway and the extrinsic pathway. The intrinsic pathway involves components that are already present in the blood and has a minor role in clotting. It is initiated by subendothelial damage, such as collagen, which leads to the formation of the primary complex on collagen by high-molecular-weight kininogen (HMWK), prekallikrein, and Factor 12. This complex activates Factor 11, which in turn activates Factor 9. Factor 9, along with its co-factor Factor 8a, forms the tenase complex, which activates Factor 10.

The extrinsic pathway, on the other hand, requires tissue factor released by damaged tissue. This pathway is initiated by tissue damage, which leads to the binding of Factor 7 to tissue factor. This complex activates Factor 9, which works with Factor 8 to activate Factor 10. Both pathways converge at the common pathway, where activated Factor 10 causes the conversion of prothrombin to thrombin. Thrombin hydrolyses fibrinogen peptide bonds to form fibrin and also activates factor 8 to form links between fibrin molecules.

Finally, fibrinolysis occurs, which is the process of clot resorption. Plasminogen is converted to plasmin to facilitate this process. It is important to note that certain factors are involved in both pathways, such as Factor 10, and that some factors are vitamin K dependent, such as Factors 2, 7, 9, and 10. The intrinsic pathway can be assessed by measuring the activated partial thromboplastin time (APTT), while the extrinsic pathway can be assessed by measuring the prothrombin time (PT).